Two Tumors, One Word People Keep Confusing: Carcinoma Versus Neuroendocrine Tumors Explained

A neuroendocrine tumor can technically be called a carcinoma, but the two terms describe fundamentally different things, and confusing them can genuinely change how a diagnosis is understood. Here is exactly where the distinction lies.

Why This Distinction Trips Up So Many People

Confused about the difference between carcinoma and neuroendocrine tumors? While both are types of cancer, they behave very differently in terms of growth, symptoms, diagnosis, and treatment. In this post, we break down carcinoma vs neuroendocrine tumor using a clinical case study of a pancreatic mass, a detailed comparison table, and key insights on how doctors make the distinction. Understanding these differences can be crucial for early diagnosis and better treatment outcomes.

Few areas of oncology generate as much genuine confusion as the relationship between carcinoma and neuroendocrine tumors, and the confusion is understandable, since the two terms are not entirely separate categories the way, say, a carcinoma and a sarcoma are. A neuroendocrine tumor can, in certain circumstances, correctly be described using the word carcinoma, which makes the two terms sound interchangeable when they are actually describing two different classification systems layered on top of each other.

Untangling this requires separating two distinct questions that pathology asks about any tumor: what type of cell it arose from, and how aggressively it is behaving. Carcinoma answers the first question in one specific way; neuroendocrine tumor classification answers a related but genuinely different question, and understanding both, and where they overlap is essential to correctly interpreting a diagnosis rather than assuming the terms mean the same thing. The distinction is not academic hairsplitting; it directly shapes treatment decisions and how a prognosis should actually be understood.

What Carcinoma Actually Means

Carcinoma is a broad term describing cancer that arises from epithelial cells, the cells that line the surfaces and cavities of organs throughout the body, including the skin, the lining of the digestive tract, the lungs, and glandular tissue such as the breast, thyroid, and prostate. Because epithelial tissue makes up such a large proportion of the body’s organs, carcinoma is, by a wide margin, the most common broad category of cancer, accounting for the vast majority of cancer diagnoses overall, including common cancers like breast, lung, colon, and prostate cancer.

Carcinoma itself is further divided into subtypes based on the specific epithelial cell type involved, including adenocarcinoma, arising from glandular epithelial cells and among the most common carcinoma subtypes, and squamous cell carcinoma, arising from flat, scale-like epithelial cells found in the skin and the lining of certain organs. This subtyping matters clinically because different carcinoma subtypes behave and respond to treatment differently, even when they technically fall under the same broad carcinoma umbrella term.

What Neuroendocrine Tumors Actually Are

Neuroendocrine tumors, commonly abbreviated NETs, arise from neuroendocrine cells, a specialized cell type found scattered throughout the body, most densely in the digestive tract, pancreas, and lungs, that share features of both nerve cells and hormone-producing endocrine cells. These cells are responsible for producing hormones and signaling molecules that regulate various bodily functions, including digestion, blood sugar regulation, and blood vessel tone, and a defining feature of many neuroendocrine tumors is their capacity to continue producing these same hormones and signaling molecules even after becoming cancerous, sometimes at levels significant enough to cause a recognizable clinical syndrome.

This hormone-producing capability is genuinely distinctive to neuroendocrine tumors and is not typically a feature of ordinary carcinomas, which is one of the most clinically important practical differences between the two categories: a neuroendocrine tumor can cause symptoms directly related to excess hormone production, flushing, diarrhea, or dangerously low blood sugar, depending on which hormone is being overproduced, symptoms that would not occur with a standard, non-hormone-producing carcinoma of similar size and location.

A neuroendocrine tumor can make a patient sick from the hormones it produces, not just from its physical size, a distinction ordinary carcinomas simply do not share.

Where the Overlap Actually Comes From

The genuine source of confusion is this: neuroendocrine cells are considered a specialized subset of cells with epithelial characteristics, meaning a cancer arising from them can, in certain classification contexts, technically be grouped within the broader carcinoma category, specifically termed neuroendocrine carcinoma, a designation generally reserved for the most aggressive, poorly differentiated end of the neuroendocrine tumor spectrum. This is precisely where the terminology overlap originates, and it is also exactly why the distinction matters clinically rather than being a purely academic naming technicality.

In current pathology classification systems, neuroendocrine neoplasms are generally divided into well-differentiated neuroendocrine tumors, which tend to behave less aggressively and grow more slowly, and poorly differentiated neuroendocrine carcinomas, which behave considerably more aggressively, grow and spread faster, and are treated with a fundamentally different treatment approach closer to that used for small cell lung cancer than the approach used for a typical, well-differentiated neuroendocrine tumor.

Differentiation: The Concept That Actually Matters Most

The single most important concept for understanding where a given neuroendocrine neoplasm falls on this spectrum is differentiation, a pathology term describing how closely tumor cells resemble the normal, healthy cells they originated from when examined under a microscope. Well-differentiated tumor cells still closely resemble normal neuroendocrine cells in appearance and organization, and this resemblance generally correlates with slower growth and a less aggressive clinical course. Poorly differentiated cells look considerably more abnormal and disorganized under the microscope, a pattern that correlates with faster growth, a greater tendency to spread, and a generally more aggressive disease course.

This differentiation assessment, combined with a measurement called the Ki-67 proliferation index, which quantifies what percentage of tumor cells are actively dividing at the time of biopsy, together form the backbone of how pathologists grade neuroendocrine neoplasms, ultimately determining whether a specific tumor is classified as a low-grade, well-differentiated neuroendocrine tumor or a high-grade, poorly differentiated neuroendocrine carcinoma, a distinction that carries direct, significant implications for treatment choice and overall prognosis.

Why Grade Matters More Than the Word Itself

This grading system is precisely why two tumors, both technically neuroendocrine neoplasms arising from the same organ, can have dramatically different treatment plans and outlooks depending entirely on their differentiation grade rather than their tissue of origin alone. A well-differentiated, low-grade neuroendocrine tumor of the pancreas, for example, may be managed with surgery alone and monitored over years with a genuinely favorable long-term outlook, while a poorly differentiated neuroendocrine carcinoma of the pancreas requires aggressive combination chemotherapy similar to small cell lung cancer treatment protocols, reflecting its considerably more aggressive underlying biology despite arising from a similar cell type in a similar location.

This is why oncologists and pathologists place such heavy emphasis on obtaining an accurate differentiation grade and Ki-67 index at diagnosis, since the grade, not simply the presence of the word carcinoma or tumor in the diagnosis, is what actually drives the treatment decision-making process and gives patients and families a meaningfully accurate sense of what to expect going forward.

Where Neuroendocrine Tumors Most Commonly Arise

Neuroendocrine tumors can develop nearly anywhere neuroendocrine cells are present, but certain locations are considerably more common than others. The gastrointestinal tract, particularly the small intestine, stomach, and rectum, accounts for a substantial share of all neuroendocrine tumor diagnoses, followed by the pancreas, where neuroendocrine tumors represent a genuinely distinct category from the far more common and considerably more aggressive pancreatic adenocarcinoma, a distinction with major prognostic significance that patients and families benefit from understanding clearly at diagnosis.

The lungs represent another significant site, where neuroendocrine tumors span a spectrum from low-grade typical carcinoid tumors to the considerably more aggressive small cell lung cancer, itself technically classified as a poorly differentiated, high-grade neuroendocrine carcinoma, illustrating once again how the same broad neuroendocrine cell origin can produce disease ranging from indolent and highly treatable to among the most aggressive cancers encountered in clinical oncology.

The Hormone-Related Symptoms Worth Knowing About

Because many neuroendocrine tumors actively secrete hormones, a meaningful subset of patients present with symptoms directly tied to hormone excess rather than symptoms related to the tumor’s physical size or location, a genuinely distinctive clinical pattern compared to most ordinary carcinomas. Carcinoid syndrome, caused by excess serotonin and related compounds typically from a neuroendocrine tumor that has spread to the liver, produces flushing, diarrhea, and in some cases heart valve damage from long-term hormone exposure.

Other functional neuroendocrine tumors can cause distinct hormone-driven syndromes depending on which hormone is overproduced, including dangerously low blood sugar from excess insulin production, severe peptic ulcer disease from excess gastrin, or a specific pattern of diabetes, gallstones, and digestive symptoms from excess somatostatin, each syndrome offering its own diagnostic clue that can sometimes lead to a neuroendocrine tumor diagnosis well before the primary tumor itself is large enough to be found through imaging alone.

How These Tumors Are Actually Diagnosed

Diagnosing and correctly classifying a suspected neuroendocrine tumor requires a combination of imaging, laboratory testing, and tissue biopsy working together. Specialized imaging techniques, including somatostatin receptor imaging, which specifically targets receptors commonly found on neuroendocrine tumor cells, can help both locate the primary tumor and identify whether it has spread, often with greater sensitivity for this specific tumor type than standard imaging alone.

Blood and urine tests measuring specific hormone levels or their breakdown products, including chromogranin A, a general neuroendocrine tumor marker, and 5-HIAA, a serotonin breakdown product elevated in carcinoid syndrome, can support the diagnosis and help monitor treatment response over time. Ultimately, tissue biopsy remains essential for confirming the diagnosis definitively and, critically, determining the differentiation grade and Ki-67 index that will actually guide treatment planning, since imaging and blood tests alone cannot reliably establish this grading information on their own.

How Treatment Approaches Genuinely Differ

Treatment for well-differentiated, low-grade neuroendocrine tumors often centers on surgical removal when the tumor is localized, and for tumors that have spread or cannot be fully removed, a range of targeted approaches specific to this tumor type, including somatostatin analog medications that both control hormone-related symptoms and can slow tumor growth, and peptide receptor radionuclide therapy, a specialized treatment delivering targeted radiation directly to tumor cells expressing somatostatin receptors, an approach genuinely distinct from standard chemotherapy protocols used for most other cancer types.

Poorly differentiated neuroendocrine carcinomas, by contrast, are generally treated with aggressive platinum-based combination chemotherapy regimens similar to those used for small cell lung cancer, reflecting their more aggressive underlying biology and the corresponding need for a more intensive treatment approach, a genuinely different treatment philosophy from the more targeted, often better-tolerated approaches used for well-differentiated tumors, further underscoring why accurate grading at diagnosis carries such direct, practical treatment implications.

Why Prognosis Varies So Dramatically Within This Category

Prognosis for neuroendocrine neoplasms spans an unusually wide range compared to many other cancer categories, precisely because the category itself contains tumors of dramatically different underlying aggressiveness. Well-differentiated, low-grade neuroendocrine tumors, even when they have spread beyond their original site, often have a genuinely favorable long-term outlook, with many patients living for many years, sometimes decades, with appropriate ongoing management, a considerably more favorable pattern than most metastatic ordinary carcinomas typically show.

Poorly differentiated neuroendocrine carcinomas, conversely, generally carry a considerably more guarded prognosis, closer to that of other high-grade, aggressive cancers, reinforcing why lumping every neuroendocrine diagnosis into a single prognostic conversation without reference to the specific differentiation grade risks giving patients either unnecessarily alarming or inappropriately reassuring information relative to their actual specific diagnosis.

How Terminology Has Evolved Over Time

The terminology used to describe neuroendocrine neoplasms has shifted meaningfully over recent decades, and understanding this history helps explain some of the persistent confusion encountered in both older medical literature and casual conversation. The term “carcinoid tumor,” once used broadly to describe most neuroendocrine tumors, particularly those arising in the gastrointestinal tract and lungs, has been progressively replaced in formal pathology classification by more precise terminology specifying differentiation grade and site of origin, though “carcinoid” remains in common clinical and patient-facing use, particularly for well-differentiated tumors.

The World Health Organization has updated its formal classification system for neuroendocrine neoplasms multiple times in recent years, each revision aimed at more precisely capturing the genuine biological differences between well-differentiated and poorly differentiated disease, reflecting a broader, ongoing effort within pathology to ensure terminology tracks meaningful clinical behavior rather than historical naming convention alone, a genuinely important distinction for anyone encountering older versus more recent literature or pathology reports discussing the same general category of tumor.

The Key Distinction Worth Remembering

The clearest way to hold this distinction in mind is this: carcinoma describes a broad category of cancer defined by its cell of origin, epithelial tissue, while neuroendocrine tumor describes a cancer arising from a specific, specialized cell type with hormone-producing capability, and the two terms overlap specifically at the aggressive, poorly differentiated end of the neuroendocrine spectrum, where the term neuroendocrine carcinoma is used deliberately to signal that particular tumor’s more aggressive behavior. Understanding this overlap, rather than treating the two terms as either completely separate or fully interchangeable, is what allows an accurate, meaningful interpretation of any specific diagnosis that uses either term.

Case Study: Differentiating Carcinoma from Neuroendocrine Tumor in a Pancreatic Mass

Clinical Presentation

A 58-year-old male presented with a 4-month history of vague abdominal pain, 7 kg unintentional weight loss, intermittent diarrhea, and episodes of facial flushing. There was no history of smoking or significant family history of malignancy. Physical examination was unremarkable except for mild pallor.

Investigations 

Initial labs showed mild anemia. Liver and renal function were normal.

Imaging: Contrast CT abdomen revealed a 3.2 cm hypodense lesion in the pancreatic tail with multiple small, hyper vascular lesions in both lobes of the liver, suggestive of metastasis.

Tumor markers: CA 19-9 and CEA were within normal limits, which was inconsistent with a typical pancreatic ductal adenocarcinoma.

Histopathology & Special Tests

An ultrasound-guided biopsy of a liver lesion was performed.

Histology: Uniform tumor cells arranged in nests and trabeculae with “salt and pepper” chromatin.

Immunohistochemistry: Positive for Chromogranin A, Synaptophysin, and Ki-67 proliferation index of 4%.

Biochemical markers: Serum Chromogranin A was elevated. 24-hour urine 5-HIAA was also raised.

Diagnosis 

Based on imaging, histology, and IHC, the diagnosis was *Grade 2 Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET) with liver metastasis.

Key Learning 

This case highlights that not all pancreatic masses are ductal carcinomas. When imaging and tumor markers don’t align with a typical carcinoma, considering a neuroendocrine tumor and ordering IHC and specific biomarkers is critical for correct classification and treatment planning.

Carcinoma vs Neuroendocrine Tumor: Quick Comparison

Frequently Asked Questions

⚕️Medical Disclaimer:

The information provided on this website is for general educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.